Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

被引：24

作者：

Arance, Ana Maria

de la Cruz-Merino, Luis

Petrella, Teresa M.

Jamal, Rahima

Ny, Lars

Carneiro, Ana

Berrocal, Alfonso

Marquez-Rodas, Ivan

Spreafico, Anna

Atkinson, Victoria

Svedman, Fernanda Costa

Mant, Andrew

Smith, Alan D.

Chen, Ke

Diede, Scott J.

Krepler, Clemens

Long, Georgina V.

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Hosp Univ Virgen Macarena, Seville, Spain

[3] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[4] Ctr Hosp Univ Montreal, Montreal, ON, Canada

[5] Univ Gothenburg, Gothenburg, Sweden

[6] Sahlgrens Univ Hosp, Gothenburg, Sweden

[7] Skane Univ Hosp, Lund, Sweden

[8] Lund Univ, Lund, Sweden

[9] Hosp Gen Univ Valencia, Valencia, Spain

[10] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[11] CIBERONC, Madrid, Spain

[12] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[13] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia

[14] Karolinska Univ Hosp, Stockholm, Sweden

[15] Monash Univ, Eastern Hlth, Melbourne, Vic, Australia

[16] Eisai Ltd, Hatfield, Herts, England

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Univ Sydney, Royal North Shore & Mater Hosp, Melanoma Inst Australia, Sydney, NSW, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9504

引用

页数：3